Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
8.21
-0.07 (-0.85%)
Nov 4, 2024, 4:00 PM EST - Market closed
Theravance Biopharma Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for TBPH stock have an average target of 13.75, with a low estimate of 9.00 and a high estimate of 21. The average target predicts an increase of 67.48% from the current stock price of 8.21.
Analyst Consensus: Buy
* Price targets were last updated on Sep 16, 2024.
Analyst Ratings
The average analyst rating for TBPH stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +82.70% | Sep 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $20 → $15 | Strong Buy | Maintains | $20 → $15 | +82.70% | Aug 6, 2024 |
| TD Cowen | TD Cowen | Hold Maintains $10 → $9 | Hold | Maintains | $10 → $9 | +9.62% | Aug 6, 2024 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $15 → $10 | Buy → Hold | Downgrades | $15 → $10 | +21.80% | Aug 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +143.61% | May 29, 2024 |
Financial Forecast
Revenue This Year
61.40M
from 57.42M
Increased by 6.93%
Revenue Next Year
89.22M
from 61.40M
Increased by 45.31%
EPS This Year
-1.03
from -1.00
EPS Next Year
0.06
from -1.03
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 67.3M | 129.2M | 182.7M | ||
| Avg | 61.4M | 89.2M | 119.9M | ||
| Low | 56.0M | 57.6M | 76.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 17.2% | 110.3% | 104.8% | ||
| Avg | 6.9% | 45.3% | 34.4% | ||
| Low | -2.6% | -6.1% | -14.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.95 | 0.64 | 1.36 | ||
| Avg | -1.03 | 0.06 | 0.33 | ||
| Low | -1.12 | -0.67 | -1.38 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 2,051.8% | ||
| Avg | - | - | 428.6% | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.